ALCON's VEXOL OPHTHALMIC CORTICOSTEROID APPROVED DEC. 30 FOR TREATING POSTOP INFLAMMATION AND ANTERIOR UVEITIS; LAST 1994 NME RECEIVES PRIORITY REVIEW
Executive Summary
Alcon Labs' corticosteroid Vexol (rimexolone) was approved on Dec. 30 as the last new drug cleared by FDA during calendar year 1994. The 1% rimexolone suspension, designated "1P" (a new molecular entity given priority review), is indicated for treatment of post-operative inflammation following ocular surgery and treatment of anterior uveitis.